Cellectis S.A. (CLLS) stock
CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.06+0.02 (+1.92%)
Close on Nov 17, 2026Market cap $106.36MP/E –Yield –
Cellectis total assets
Total assets on the balance sheet at the end of each period.
Cellectis's total assets was $267.37M at Jun 30, 2026. For fiscal 2025 it was $324.72M, down 15.3% from the year before. Over ten years it grew -1.3% a year on average. The highest annual figure on record is $500.84M in fiscal 2018.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $324.72M | -15.3% |
| FY2024 | Dec 31, 2024 | $383.54M | +14.7% |
| FY2023 | Dec 31, 2023 | $334.27M | +28.0% |
| FY2022 | Dec 31, 2022 | $261.22M | -31.6% |
| FY2021 | Dec 31, 2021 | $382.08M | -18.6% |
| FY2020 | Dec 31, 2020 | $469.47M | +0.4% |
| FY2019 | Dec 31, 2019 | $467.47M | -6.7% |
| FY2018 | Dec 31, 2018 | $500.84M | +50.5% |
| FY2017 | Dec 31, 2017 | $332.88M | +0.4% |
| FY2016 | Dec 31, 2016 | $331.43M | -10.7% |
| FY2015 | Dec 31, 2015 | $371.31M | +122.2% |
| FY2014 | Dec 31, 2014 | $167.08M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $267.37M | -34.3% |
| Q4 FY2025 | Dec 31, 2025 | $324.72M | -2.9% |
| Q2 FY2025 | Jun 30, 2025 | $353.97M | +68.8% |
| Q4 FY2024 | Dec 31, 2024 | $383.54M | +68.5% |
| Q2 FY2024 | Jun 30, 2024 | $407.15M | +55.9% |
| Q4 FY2023 | Dec 31, 2023 | $334.27M | +4.2% |
| Q3 FY2023 | Sep 30, 2023 | $209.70M | -45.1% |
| Q2 FY2023 | Jun 30, 2023 | $227.67M | -50.2% |
| Q4 FY2022 | Dec 31, 2022 | $261.22M | -44.4% |
| Q2 FY2022 | Jun 30, 2022 | $320.88M | -32.1% |
| Q4 FY2021 | Dec 31, 2021 | $382.08M | -18.3% |
| Q2 FY2021 | Jun 30, 2021 | $457.57M | -8.6% |
| Q4 FY2020 | Dec 31, 2020 | $469.47M | +41.0% |
| Q2 FY2020 | Jun 30, 2020 | $472.70M | +42.6% |
| Q4 FY2019 | Dec 31, 2019 | $467.47M | +25.9% |
| Q4 FY2018 | Dec 31, 2018 | $500.84M | +199.8% |
| Q4 FY2017 | Dec 31, 2017 | $332.88M | – |
| Q4 FY2016 | Dec 31, 2016 | $331.43M | – |
| Q4 FY2015 | Dec 31, 2015 | $371.31M | – |
| Q4 FY2014 | Dec 31, 2014 | $167.08M | – |
See a number that looks wrong?